In our system of accrediting continuing education, we have built into that system very strong and strict safeguards against bias and lack of balance entry into the programs where you get credits. We're very stringent on ensuring that the evidence that's put in front of our members around the education they get on prescribing, among many other things, is based on science and not on marketing. That's a clear requirement that we have.
Dr. Simpson mentioned the success that pharmaceutical companies have had with detailing. I completely agree with him that we could take a lesson from that. One of the interventions that we know succeeds—and pharmaceutical companies have known this forever—is establishing a relationship with a prescriber in the context of education. The only reason we can't do that is resources. Resources need to be applied by us around presenting scientific rather than marketing to prescribers that would allow for a broad range of important clinical decision-making questions to be addressed with members of the health care team at all levels.